Fuzhou General Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

QYJD Compound Preparation Promotes Rapid Postoperative Recovery in Early-stage NSCLC Patients by Regulating Tissue Microecology: a Prospective, Randomized Controlled, Open-label, Phase I Clinical Study With Predefined Future Exploration

Phase 1

Completed

Conditions: NSCLC

Interventions: Drug: QYJD Compound Preparation

First Posted Date: 2025-01-09

Last Posted Date: 2025-01-09

Lead Sponsor: Fuzhou General Hospital

Target Recruit Count: 15

Registration Number: NCT06766565

Locations: 🇨🇳
Zongyang Yu, Fujian, Fuzhou, China

Defining COVID-19 Infection Severity on Presentation to Hospital

Recruiting

Conditions: Infections
Morality
COVID-19
Death, Assisted

Interventions: Diagnostic Test: Supportive treatment (BSC)
Diagnostic Test: Medical observation
Diagnostic Test: Intensive care management

First Posted Date: 2023-01-10

Last Posted Date: 2023-01-10

Lead Sponsor: Fuzhou General Hospital

Target Recruit Count: 3000

Registration Number: NCT05677789

Locations: 🇨🇳
The 900th Hospital of the Joint Logistic Support Force, PLA, Fuzhou, Fujian, China

The Efficacy and Safety of Azovudine in the Treatment of COVID-19

Recruiting

Conditions: COVID-19
Infections
Morality
Death, Assisted

Interventions: Drug: Azorubine

First Posted Date: 2023-01-09

Last Posted Date: 2023-01-10

Lead Sponsor: Fuzhou General Hospital

Target Recruit Count: 500

Registration Number: NCT05675761

Locations: 🇨🇳
The 900th Hospital of the Joint Logistic Support Force, PLA, Fuzhou, Fujian, China

Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Immunotherapy Esophagus Cancer

Interventions: Drug: Tislelizumab
Drug: Albumin paclitaxel
Drug: Nedaplatin
Radiation: radiotherapy

First Posted Date: 2022-08-25

Last Posted Date: 2024-02-07

Lead Sponsor: Fuzhou General Hospital

Target Recruit Count: 93

Registration Number: NCT05515315

Locations: 🇨🇳
Ye zai sheng, Fuzhou, Fujian, China

ctDNA as a Biomarker for Treatment in Advanced NSCLC

Not yet recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Immunotherapy
Drug: Chemotherapeutic Agent
Drug: Chemotherapy

First Posted Date: 2022-08-04

Last Posted Date: 2022-08-04

Lead Sponsor: Fuzhou General Hospital

Target Recruit Count: 500

Registration Number: NCT05486988

Locations: 🇨🇳
900TH Hospital of Joint Logisti'cs Support Force, Fuzhou, Fujian, China

Peginterferon Alpha-2b Therapy in Chronic Hepatitis Patients With Normal ALT Level and Low Viremia

Phase 1

Conditions: Chronic Hepatitis B Patients With a Normal ALT Level and Low Viremia

Interventions: Drug: Peginterferon alpha-2b
Drug: pulse peginterferon alpha-2b
Drug: Nucleotide Analog

First Posted Date: 2022-01-24

Last Posted Date: 2022-01-24

Lead Sponsor: Fuzhou General Hospital

Target Recruit Count: 300

Registration Number: NCT05203055

Locations: 🇨🇳
Fuzhou General Hospital, Xiamen Univ, Fuzhou, Fujian, China

Camrelizumab Combined With Radiotherapy for Adjuvant Treatment of Esophageal Squamous Cell Carcinoma After Surgery

Not Applicable

Conditions: Esophageal Squamous Cell Carcinomas

Interventions: Drug: Camrelizumab
Radiation: radiotherapy

First Posted Date: 2021-02-05

Last Posted Date: 2021-02-05

Lead Sponsor: Fuzhou General Hospital

Target Recruit Count: 20

Registration Number: NCT04741490

Locations: 🇨🇳
Fuzhou General Hospital, Fuzhou, Fujian, China

Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.

Phase 3

Conditions: Lung Neoplasm
Small Cell Lung Cancer
PD-1 Inhibitors

Interventions: Drug: Camrelizumab combined with Apatinib, Etoposide and Cisplatin

First Posted Date: 2020-07-29

Last Posted Date: 2021-02-08

Lead Sponsor: Fuzhou General Hospital

Target Recruit Count: 45

Registration Number: NCT04490421

Locations: 🇨🇳
The 900th Hospital of Joint Logistic Support Force, Fuzhou, Fujian, China

Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019

Early Phase 1

Conditions: COVID-19 Pneumonia

Interventions: Drug: Oseltamivir
Drug: hormones
Device: oxygen therapy
Procedure: mesenchymal stem cells

First Posted Date: 2020-05-01

Last Posted Date: 2020-05-01

Lead Sponsor: Fuzhou General Hospital

Target Recruit Count: 60

Registration Number: NCT04371601

Locations: 🇨🇳
Fuzhou General Hospital, Fuzhou, Fujian, China

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

Phase 2

Conditions: Breast Cancer Female
HER2-positive Breast Cancer
Hormone Receptor Positive Malignant Neoplasm of Breast
Metastatic Breast Cancer
Breast Diseases
Hormone Receptor Positive Tumor

Interventions: Drug: Pyrotinib
Drug: Trastuzumab
Drug: Aromatase Inhibitors

First Posted Date: 2019-09-12

Last Posted Date: 2019-09-12

Lead Sponsor: Fuzhou General Hospital

Target Recruit Count: 77

Registration Number: NCT04088110

Locations: 🇨🇳
Fuzhou general hospital, Fuzhou, Fujian, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy